MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization
MeiraGTx has secured significant funding from Oberland Capital to accelerate the commercialization of two gene therapies.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
MeiraGTx has obtained a funding package from Oberland Capital to support the commercialization of two gene therapies. According to various reports, this financial arrangement includes up to $375 million in royalty financing and $10 million in equity, though some coverage values the total new funding pathways at $425 million. Coverage from Fierce Biotech and TradingView emphasizes that the funds will be used for commercialization efforts and to retire Perceptive debt.
Seeking Alpha reports on additional catalysts, including BLA filing for AAV2-hAQP1 in the first half of 2027 and the Bota-Vec acquisition. Investing.com notes that H.C. Wainwright has reiterated its stock rating following the deal.
Future developments include the anticipated BLA filing for AAV2-hAQP1 in the first half of 2027 and the progress of the two gene therapies moving toward commercialization.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
How much funding did MeiraGTx secure?
Reports vary, with Fierce Biotech citing $400 million, TradingView specifying $375 million in royalty financing and $10 million in equity, and simplywall.st mentioning $425 million in funding pathways.
What is the purpose of the financing?
The funds are intended to help get two gene therapies to commercialization and to retire Perceptive debt.
When is the BLA filing for AAV2-hAQP1 expected?
According to Seeking Alpha, the BLA filing is expected in the first half of 2027.
Coverage (5)
- MeiraGTx Secures Up To $375 Million Royalty Financing, Adds $10 Million Equity, Retires Perceptive Debt TradingView · 23h ago
- Exclusive BAC Article: MeiraGTx; AAV2-hAQP1 Q2 207 Data Xerostomia, BLA Filing 1st Half 2027, Bota-Vec Acquisition, Oberland Capital Cash Infusion, And Catalysts (NASDAQ:MGTX) Seeking Alpha · 23h ago
- MeiraGTx Holdings (MGTX) Is Up 8.5% After Securing US$425M In New Funding Pathways simplywall.st · 23h ago
- H.C. Wainwright reiterates MeiraGTx stock rating on financing deal Investing.com · 23h ago
- MeiraGTx scores $400M from Oberland Capital to help get 2 gene therapies to commercialization Fierce Biotech · 23h ago broke it first
People, places & organizations
Topics
Related trends
Family behind top US egg producer reaped $320mn after price surge
Destroying the Privacy LED on Meta Smart Glasses Will No Longer Enable Creepiness
‘Absolutely bananas’: San Francisco homes sell for $1m above asking price amid AI boom
SF Supervisor to Launch Inquiry on Waymo's July Fourth Traffic Meltdown
San Francisco officials are investigating Waymo after autonomous vehicles reportedly blocked roads and ran out of charge during July 4 festivities.
Execs Confused and Horrified by the Huge AI Bills After Thinking They Could Replace Workers for Free
Corporate executives are facing unexpected financial shocks as the perceived promise of free AI-driven labor meets the reality of massive operational bills.